

Kyle Wright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8529416/publications.pdf>

Version: 2024-02-01

8
papers

418
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

851
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216
2	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018, 132, 92-92.	1.4	74
3	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> , 2020, 5, .	5.0	51
4	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1353-1364.	1.4	31
5	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374.	5.2	25
6	Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis. <i>Blood Advances</i> , 2020, 4, 4965-4979.	5.2	9
7	Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. <i>Leukemia and Lymphoma</i> , 2020, 61, 2258-2261.	1.3	7
8	Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence. <i>Blood</i> , 2018, 132, 678-678.	1.4	5